Journal of global antimicrobial resistance · 2026
A humanized monoclonal antibody potentiates killing of Pseudomonas aeruginosa by common antibiotics.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rhodes Jaime D, Goodman Steven D, Bakaletz Lauren O
Аннотация
OBJECTIVE: Chronic and recurrent cystic fibrosis lung infections, commonly due to the presence of recalcitrant Pseudomonas aeruginosa biofilms, are not effectively cleared with traditional antibiotics, largely due to a structurally sound and protective extracellular DNA matrix that envelopes biofilm-resident bacteria. We recently showed that when extracellular DNA architecture is disrupted by a humanized monoclonal antibody (HuTipMab) directed against the protective epitopes of universal bacterial proteins that serve as linchpins within the lattice (DNABII proteins), resident bacteria are released in a highly sensitive phenotype that renders them vulnerable to killing by host immune effectors and antibiotics.
METHODS: P. aeruginosa biofilms formed by 3 clinical isolates were incubated with media alone or HuTipMab to generate non-biofilm-associated bacteria (NBfA) or bacteria newly released from biofilm residence (NRel), respectively. Antibiotic susceptibility testing at sub-MIC concentrations was then performed on each bacterial population to determine the sensitivity of NRel to the action of antibiotics compared to their non-biofilm-associated bacteria counterparts.
RESULTS: Biofilms formed by three P. aeruginosa clinical isolates were significantly disrupted by HuTipMab prior to treatment with three commonly prescribed antibiotics for people with cystic fibrosis: colistin, aztreonam, or tobramycin. Bacteria newly released from HuTipMab-treated biofilms were significantly more susceptible to killing by each tested antibiotic compared with both their non-biofilm-associated counterparts and those resident within a biofilm.
CONCLUSIONS: Whereas antibiotics alone do not successfully clear P. aeruginosa from lungs with cystic fibrosis, we herein provide support for a novel approach toward the aforementioned goal that both independently targets biofilm infrastructure and empowers the use of traditional antibiotics.
METHODS: P. aeruginosa biofilms formed by 3 clinical isolates were incubated with media alone or HuTipMab to generate non-biofilm-associated bacteria (NBfA) or bacteria newly released from biofilm residence (NRel), respectively. Antibiotic susceptibility testing at sub-MIC concentrations was then performed on each bacterial population to determine the sensitivity of NRel to the action of antibiotics compared to their non-biofilm-associated bacteria counterparts.
RESULTS: Biofilms formed by three P. aeruginosa clinical isolates were significantly disrupted by HuTipMab prior to treatment with three commonly prescribed antibiotics for people with cystic fibrosis: colistin, aztreonam, or tobramycin. Bacteria newly released from HuTipMab-treated biofilms were significantly more susceptible to killing by each tested antibiotic compared with both their non-biofilm-associated counterparts and those resident within a biofilm.
CONCLUSIONS: Whereas antibiotics alone do not successfully clear P. aeruginosa from lungs with cystic fibrosis, we herein provide support for a novel approach toward the aforementioned goal that both independently targets biofilm infrastructure and empowers the use of traditional antibiotics.